facebook_pixel
Equity Strategy 29 April 2014
BLUE PHOENIX FINANCIALS PREMIUM CONTENT Not a member? Join Now!
Samsung: Hold. 1Q Profit Climbs 7%

Samsung: Hold. 1Q Profit Climbs 7%

* Samsung Electronics Co., the world’s largest maker of smartphones, posted first-quarter profit that beat analysts’ estimates as demand rose for cheaper Galaxy devices and the soccer World Cup boosted TV sales * Net income, excluding minority interests, rose 7 percent to 7.48 trillion won ($7.2 billion) in the three months ended March, the Suwon, South […]

FIND OUT MORE

Equity Strategy 28 April 2014
BLUE PHOENIX FINANCIALS PREMIUM CONTENT Not a member? Join Now!
Apollo Hospitals: Buy. Uptrend Has Started

Apollo Hospitals: Buy. Uptrend Has Started

* Apollo Hospitals of India is one of Asia’s largest hospital chains with 8,420 beds (owned and managed)  across 51 hospitals in India and its environs. The hospital chain also encompasses 100 neighbourhood clinics and 1,500 pharmacies. Apollo is executing its biggest expansion plan–adding 2,685 beds across 13 new hospitals over the next three years–at a […]

FIND OUT MORE

Equity Strategy 25 April 2014
BLUE PHOENIX FINANCIALS PREMIUM CONTENT Not a member? Join Now!
Microsoft: Hold Long Positions On Cloud Computing Push

Microsoft: Hold Long Positions On Cloud Computing Push

* As early as 10 Feb 2014, we advised to Buy Microsoft: http://www.bluephoenixfinancials.com/equity-strategies/microsoft-buy-cloud-computing-key/ * On 2 April 2014, Microsoft traded as high as $41.66 per share, just short of our $42.00 target price * NOTE: We now raise our target price to $44 from $42 * We advise Investors who bought Microsoft to hold on to […]

FIND OUT MORE

Equity Strategy 23 April 2014
BLUE PHOENIX FINANCIALS PREMIUM CONTENT Not a member? Join Now!
Gilead Sciences: Buy. 1Q Sovaldi Sales $2.27B

Gilead Sciences: Buy. 1Q Sovaldi Sales $2.27B

* Gilead Sciences Inc. overwhelmed sales estimates for its new blockbuster hepatitis C pill in what analysts called the biggest drug start ever, raising questions about insurers’ ability to slow the use of the costly therapy. The shares gained in early trading * Sovaldi, the company’s $1,000-a-pill medicine to treat hepatitis C, had sales of $2.27 billion in the first quarter, the […]

FIND OUT MORE

Options Strategy 23 April 2014
BLUE PHOENIX FINANCIALS PREMIUM CONTENT Not a member? Join Now!
Gilead Sciences May $70 Call Options: +41.76%. Take Profit

Gilead Sciences May $70 Call Options: +41.76%. Take Profit

* On 22 April 2014 we advised to Buy Gilead Sciences May $70 Call Options before earnings: http://www.bluephoenixfinancials.com/options-strategies/gilead-sciences-may-70-call-options-buy-earnings-today/ * On 23 April 2014, Gilead Sciences May $70 Call Options traded at $6.45, above our $6.00 target price * Investors who followed our advice made a profit of 41.76% in 1 Day * We advice Investors to […]

FIND OUT MORE